Objective:To preliminarily verify the feasibility of applying a wearable teleconsultation device in the diagnosis of common skin diseases.Methods:Totally, 600 outpatients with skin diseases were prospectively enrolled from the Department of Dermatology from November 1 to December 31 2023, and both on-site and remote diagnoses were performed. In the face-to-face clinic, there was one resident physician A and one chief physician B, while there was one resident physician C and one chief physician D in the remote consultation clinic. Using the diagnostic results of physician B in the face-to-face clinic as a reference, diagnostic agreement rates of physicians A, C, and D were calculated separately. Additionally, diagnostic results were compared between physician A and physician C, as well as between physician A and physician D. Statistical analysis was carried out using McNemar's test and Kappa consistency analysis.Results:Among the 600 patients with skin diseases, there were 285 males (47.50%) and 315 females (52.50%), and their age was 38.75 ± 21.12 years. The most common skin diseases were dermatitis and eczema (138 cases, 23.00%), followed by viral skin diseases (79 cases, 13.17%), urticaria (53 cases, 8.83%), hair diseases (53 cases, 8.83%), skin tumors (46 cases, 7.67%), fungal skin diseases (38 cases, 6.33%), etc. Compared with the physician B, the physician A made consistent diagnoses in 477 cases (79.5%) and inconsistent diagnoses in 123 cases (20.5%), the physician C made consistent diagnoses in 465 cases (77.5%) and inconsistent diagnoses in 135 cases (22.5%), and the physician D made consistent diagnoses in 568 cases (94.6%) and inconsistent diagnoses in 32 cases (5.33%). There was no significant difference in the diagnostic accuracy between the physician A and physician C ( P = 0.430), with a Kappa value of 0.852, indicating very strong consistency. The diagnostic accuracy of the physician D was significantly higher than that of the physician A ( P = 0.001), with a Kappa value of 0.274, indicating weak consistency. Conclusion:Chief dermatologists can provide medical guidance to resident physicians through a wearable teleconsultation system.

Zhishi Shaoyaosan is the 34^th prescription in the Catalogue of Ancient Classic Formulas （Second Batch） published by the National Administration of Traditional Chinese Medicine in 2023. It is widely used in clinical practice and has a definite curative effect. However， there is currently a lack of its ancient literature analysis and textual research， and there is no corresponding Chinese patent medicine preparation. By consulting and combing the relevant ancient books of traditional Chinese medicine， this paper analyzes and conducts textual research of the origin， composition， measurement， administration， and efficacy of Zhishi Shaoyaosan. The results show that Zhishi Shaoyaosan is derived from Essentials from the Golden Cabinet written by Zhang Zhongjing in the Eastern Han Dynasty. It is mainly recorded in the name of Zhishi Shaoyaosan in the literature of the past dynasties. The prescription is composed of Aurantii Fructus Immaturus and Paeoniae Radix Alba. The processing method is stir-frying Aurantii Fructus Immaturus to scorch and using raw Paeoniae Radix Alba. The dose of the prescription recorded in the ancient books is mainly an equal amount of Aurantii Fructus Immaturus and Paeoniae Radix Alba in one square-cun spoon， taken three times a day， which is converted into a modern dose of 1.5 g each time （0.75 g Aurantii Fructus Immaturus and 0.75 g Paeoniae Radix Alba each time）. The components of the prescription are ground into powder and taken with barley porridge， three times a day. The efficacy is to break stagnated Qi， harmonize blood， and relieve restlessness and pain. It is mainly used to treat postpartum abdominal pain， acute pelvic inflammatory disease， acute cholecystitis and intestinal diseases， stroke sequelae， and other diseases. This study combs and analyzes the ancient literature recording Zhishi Shaoyaosan and clarifies the key information of the prescription， which provides a basis for promoting the research and development of its patent medicine.